2325.Hk
The company operates in the healthcare sector, primarily engaged in pharmaceuticals, and generates revenue through the provision of healthcare services and equipment.
Business. The company operates in the healthcare sector, primarily engaged in pharmaceuticals, and generates revenue through the provision of healthcare services and equipment.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the healthcare sector, primarily engaged in pharmaceuticals, and generates revenue through the provision of healthcare services and equipment.
The company maintains a strong liquidity position, with cash and equivalents amounting to CNY 1.52 billion, significantly exceeding its total liabilities of CNY 1.58 billion, resulting in a current ratio of 1.59. This liquidity is further supported by a low debt-to-equity ratio of 0.6, indicating a conservative capital structure. The price-to-book ratio of 0.41 suggests that the company is trading at a discount relative to its book value, which may reflect market skepticism about its asset quality or future earnings potential.
Profitability metrics reveal a weak performance, with a return on equity of 0.0025 and a return on assets of 0.0011, both significantly below industry norms. The company's net income of CNY 2.92 million is minimal compared to its revenue of CNY 601.39 million, indicating a low margin of profitability. This is further exacerbated by an operating income of CNY 32.95 million, which is only 5.5% of total revenue.
Geographically and segment-wise, the company's exposure is not explicitly detailed in the available data, but the low net income and high operating costs suggest a potential concentration risk in its core operations. The lack of segment-specific data limits the ability to assess diversification or geographic spread.
The company's growth trajectory appears muted, with no significant revenue growth indicators provided in the data. The outlook for the current fiscal year does not suggest a substantial improvement in revenue or profitability, and the absence of analyst recommendations for a strong buy or buy indicates a cautious market sentiment.
Risk factors are minimal, with no immediate liquidity or dilution flags detected. The company's low dilution potential and stable share count suggest a conservative approach to capital management. However, the low return on equity and assets highlight operational inefficiencies that could pose long-term risks to profitability.
Recent events, including filings and transcripts, do not show any significant developments that would impact the company's financial position or market perception. The absence of strong analyst recommendations and the low net income suggest that the company may be facing challenges in maintaining its competitive position in the healthcare sector.
- The company has a strong liquidity position with a current ratio of 1.59 and a low debt-to-equity ratio of 0.6.
- Profitability is weak, with a return on equity of 0.0025 and a return on assets of 0.0011.
- The company's net income is minimal compared to its revenue, indicating a low margin of profitability.
- There are no immediate liquidity or dilution flags, suggesting a conservative capital structure.
- Analysts have not issued strong buy or buy recommendations, indicating a cautious market sentiment.
- **margin_outlook_rationale**: The company's low net income and operating income suggest that margin pressures are likely to persist due to high operating costs.
- **rd_outlook_rationale**: No specific data on R&D expenditures is provided, but the low profitability may indicate limited investment in innovation.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- 2325.HK Market data — financials · 2026-05-26
- Yunkang Group Ltd Market data — analyst estimates · 2026-05-26
Ownership & reference
Leadership
- Xubo WangExecutive Vice President